On the stock market since 2022, it operates in the world of health and science. It has 87 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year). Red columns mark years that ended in a loss.
The gap is $4.1M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 209% — still a thick cushion, though costs have been eating into it lately.
Over the last 12 months, company executives reported 10 buys and 2 sells. Management buying with its own money is usually read as a good sign.
Over the last 3 years, sales fell about 7% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, NIVF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NIVF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.